Investment Thesis
Phreesia exhibits weak fundamental characteristics including anemic 2.7% revenue growth, dangerously thin profit margins (2.3% net, 5.2% operating), and poor returns on capital (0.8% ROE, 0.4% ROA). While the balance sheet is solid and free cash flow is positive, the business fails to generate attractive returns relative to its $666M asset base, indicating capital allocation challenges in a competitive healthcare IT market.
Strengths
- Fortress balance sheet with minimal debt ($612K long-term) and $76.4M cash position
- Positive free cash flow generation ($19.6M, 15% FCF margin) demonstrates underlying cash generation despite thin net profitability
- Strong liquidity position (1.76x current ratio) provides financial flexibility and operational stability
Risks
- Stagnant revenue growth of 2.7% YoY is unacceptable for a technology-enabled healthcare platform and signals market saturation or competitive displacement
- Severely compressed profit margins (2.3% net, 5.2% operating) indicate structural competitive pressure, pricing power loss, or uncontrolled cost structure in commoditized market
- Abysmal return metrics (0.8% ROE, 0.4% ROA) demonstrate the business cannot efficiently deploy capital, with $666M in assets generating only $3M net income annually
Key Metrics to Watch
- YoY revenue growth acceleration above 10% - critical to prove market relevance and growth runway
- Operating margin expansion to minimum 12-15% - essential to demonstrate sustainable profitability and operational leverage
- Return on equity improvement above 5-8% - necessary to validate efficient capital deployment and shareholder value creation
Financial Metrics
Revenue
130.9M
Net Income
3.0M
EPS (Diluted)
$0.05
Free Cash Flow
19.6M
Total Assets
666.1M
Cash
76.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
5.2%
Net Margin
2.3%
ROE
0.8%
ROA
0.4%
FCF Margin
15.0%
Balance Sheet & Liquidity
Current Ratio
1.76x
Quick Ratio
1.76x
Debt/Equity
0.00x
Debt/Assets
46.1%
Interest Coverage
3.64x
Long-term Debt
612.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-29T07:49:15.557848 |
Data as of: 2026-04-30 |
Powered by Claude AI